Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
(2013).
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting..
Oncotarget. 7(22), 32731-53.
(2016). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012). Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer..
Oncotarget. 9(86), 35623-35638.
(2018). Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data..
Int J Neuropsychopharmacol. 14(3), 405-12.
(2011). No differences between drug naive and drug experienced unipolar depressed patients in terms of neurobiological testing: a cross sectional study..
J Psychiatr Res. 47(12), 1984-90.
(2013). Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis..
Ann Gen Psychiatry. 8, 27.
(2009). The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia..
CNS Spectr. 1-25.
(2020). Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study..
Pharmacopsychiatry. 52(4), 193-202.
(2019). Brain Volume Changes Under Treatment With Antipsychotics..
JAMA Psychiatry. 77(8), 876-877.
(2020). Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue..
J Psychopharmacol. 26(5), 744-50.
(2012). [Non-conventional pharmacological agents for the treatment of bipolar disorder: Α systematic review of the evidence]..
Psychiatriki. 27(4), 253-263.
(2016). DSM-III-R change in definition might have affected placebo response to antidepressants..
Lancet Psychiatry. 4(1), 21-22.
(2017). Neurological soft signs in familial and sporadic schizophrenia..
Psychiatry Res. 272, 222-229.
(2019). The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder..
Int J Neuropsychopharmacol. 23(4), 230-256.
(2020). Corrigendum to "Neurological soft signs significantly differentiate schizophrenia patients from healthy controls"; [Acta Neuropsychiatrica 2018;30(2):97-105]..
Acta Neuropsychiatr. 31(1), 61.
(2019). Standardization of the TEMPS-A in the Greek general population..
J Affect Disord. 158, 19-29.
(2014). One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study..
Clin Psychopharmacol Neurosci. 18(3), 434-444.
(2020). Treatment guidelines for mental disorders: reality or illusion?.
Psychiatriki. 26(2), 89-92.
(2015). Past, present and future in the treatment of major psychotic disorders..
Curr Pharm Des. 18(12), 1557.
(2012). The right to choose treatment-without-treatment: respecting civil rights or an unprecedented manifestation of 'reverse stigma'?.
Acta Neuropsychiatr. 31(1), 56-58.
(2019). Life events and dementia: what is the nature of their relationship?.
Psychiatry Res. 190(1), 156-8.
(2011). Climate change but not unemployment explains the changing suicidality in Thessaloniki Greece (2000-2012)..
J Affect Disord. 193, 331-8.
(2016). Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis..
J Affect Disord. 133(3), 361-70.
(2011). First reliable data suggest a possible increase in suicides in Greece..
BMJ. 347, f4900.
(2013).